BR0112998A - Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamento - Google Patents

Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamento

Info

Publication number
BR0112998A
BR0112998A BR0112998-8A BR0112998A BR0112998A BR 0112998 A BR0112998 A BR 0112998A BR 0112998 A BR0112998 A BR 0112998A BR 0112998 A BR0112998 A BR 0112998A
Authority
BR
Brazil
Prior art keywords
treatment
disorders
compound
pharmaceutical composition
nervous system
Prior art date
Application number
BR0112998-8A
Other languages
English (en)
Inventor
Jakob Felding
Kim Andersen
Benny Bang-Andersen
Garrick Paul Smith
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR0112998A publication Critical patent/BR0112998A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"DERIVADOS DE INDOL úTEIS PARA O TRATAMENTO DE DISTúRBIOS DO SISTEMA NERVOSO CENTRAL (SNC); COMPOSTO; SUA UTILIZAçãO; COMPOSIçãO FARMACêUTICA E MéTODO DE TRATAMENTO". A presente invenção refere-se a ligandos de receptor de serotonina e dopamina possuindo a fórmula geral (I), onde os significados de R^ 1^ - R^ 9^, W, n e X são conforme o fornecido nas reivindicações e na descrição. Os compostos da invenção são úteis no tratamento de certos distúrbios psiquiátricos e neurológicos, ou seja, esquizofrenia, outras psicoses, distúrbios de ansiedade, depressão, enxaqueca, distúrbios cognitivos, ADHD e na melhora de sono.
BR0112998-8A 2000-07-21 2001-07-17 Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamento BR0112998A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001123 2000-07-21
PCT/DK2001/000507 WO2002008223A1 (en) 2000-07-21 2001-07-17 Indole derivatives useful for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
BR0112998A true BR0112998A (pt) 2003-06-24

Family

ID=8159625

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112998-8A BR0112998A (pt) 2000-07-21 2001-07-17 Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamento

Country Status (29)

Country Link
US (1) US6743809B2 (pt)
EP (1) EP1305307B1 (pt)
JP (1) JP2004504396A (pt)
KR (1) KR100851793B1 (pt)
CN (1) CN1264838C (pt)
AR (1) AR029858A1 (pt)
AT (1) ATE266024T1 (pt)
AU (2) AU2001281738B2 (pt)
BG (1) BG107528A (pt)
BR (1) BR0112998A (pt)
CA (1) CA2416212C (pt)
CZ (1) CZ301114B6 (pt)
DE (1) DE60103162T2 (pt)
EA (1) EA004749B1 (pt)
ES (1) ES2219554T3 (pt)
HK (1) HK1059782A1 (pt)
HR (1) HRP20030015A2 (pt)
HU (1) HUP0302820A3 (pt)
IL (2) IL153605A0 (pt)
IS (1) IS2172B (pt)
MX (1) MXPA02012927A (pt)
NO (1) NO323799B1 (pt)
NZ (1) NZ523436A (pt)
PT (1) PT1305307E (pt)
SK (1) SK286701B6 (pt)
TR (1) TR200401488T4 (pt)
UA (1) UA73995C2 (pt)
WO (1) WO2002008223A1 (pt)
ZA (1) ZA200300287B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004291297B2 (en) 2003-11-17 2011-06-23 Boehringer Ingelheim International Gmbh Novel piperidine-substituted indoles- or heteroderivatives thereof
TWI391387B (zh) * 2004-05-12 2013-04-01 Eisai R&D Man Co Ltd 具有哌啶環之吲哚衍生物
WO2006117314A2 (en) 2005-04-30 2006-11-09 Boehringer Ingelheim International Gmbh Novel piperidin- substituted indoles and their use as ccr-3 modulators
CA2667547C (en) 2006-10-27 2014-07-29 Boehringer Ingelheim International Gmbh Piperidyl-propane-thiol ccr3 modulators
CN101486654B (zh) * 2009-03-04 2012-10-10 西安近代化学研究所 2-甲基-3-硝基苯乙酸合成方法
CN110041318B (zh) * 2018-01-17 2022-07-29 中国科学院上海药物研究所 一类多巴胺d5受体激动剂及其制备和应用
CN110498789B (zh) * 2018-05-17 2022-04-05 上海医药工业研究院 芳烷哌啶类衍生物及其在多靶点抗抑郁症中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2322470A1 (de) * 1973-05-04 1974-11-21 Boehringer Sohn Ingelheim Neue indolyl-piperidino-(bzw. 1,2,5,6tetrahydro-pyridyl-)butyrophenone und verfahren zu ihrer herstellung
AT332401B (de) * 1973-11-26 1976-09-27 Roussel Uclaf Verfahren zur herstellung von neuen (4'-(3''-indolyl)-piperidino)-alkylarylketonderivaten
US4997841A (en) * 1987-08-13 1991-03-05 Glaxo Group Limited Indole derivatives
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
CA2141810A1 (en) * 1992-08-05 1994-02-17 Ian A. Cliffe Amide derivatives
DK0695301T3 (da) * 1993-04-22 1996-12-09 Pfizer Ltd Indolderivater som 5-HT1-lignende agonister til anvendelse ved migræne
ES2063700B1 (es) * 1993-04-28 1995-07-16 Vita Invest Sa Agente activo sobre el sistema nervioso central, proceso para su preparacion y composiciones farmaceuticas que lo contengan.
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
GB9718712D0 (en) * 1997-09-03 1997-11-12 Merck Sharp & Dohme Theraputic Agents

Also Published As

Publication number Publication date
AU2001281738B2 (en) 2006-12-21
EP1305307B1 (en) 2004-05-06
AU8173801A (en) 2002-02-05
ES2219554T3 (es) 2004-12-01
CA2416212A1 (en) 2002-01-31
KR20030017643A (ko) 2003-03-03
ATE266024T1 (de) 2004-05-15
TR200401488T4 (tr) 2004-08-23
PT1305307E (pt) 2004-09-30
PL359157A1 (en) 2004-08-23
NO323799B1 (no) 2007-07-09
IS2172B (is) 2006-11-15
BG107528A (bg) 2003-10-31
NZ523436A (en) 2004-07-30
IS6663A (is) 2002-12-23
MXPA02012927A (es) 2003-05-15
DE60103162D1 (de) 2004-06-09
CN1264838C (zh) 2006-07-19
KR100851793B1 (ko) 2008-08-13
HUP0302820A3 (en) 2006-04-28
CZ2003196A3 (cs) 2003-05-14
IL153605A (en) 2008-07-08
HK1059782A1 (en) 2004-07-16
IL153605A0 (en) 2003-07-06
HUP0302820A2 (hu) 2003-12-29
AR029858A1 (es) 2003-07-16
WO2002008223A1 (en) 2002-01-31
CN1451002A (zh) 2003-10-22
CA2416212C (en) 2007-10-30
SK2032003A3 (en) 2003-06-03
NO20030127L (no) 2003-01-10
ZA200300287B (en) 2004-03-02
CZ301114B6 (cs) 2009-11-11
DE60103162T2 (de) 2005-05-04
JP2004504396A (ja) 2004-02-12
UA73995C2 (en) 2005-10-17
US20030166664A1 (en) 2003-09-04
HRP20030015A2 (en) 2005-02-28
EA200300179A1 (ru) 2003-06-26
US6743809B2 (en) 2004-06-01
EA004749B1 (ru) 2004-08-26
SK286701B6 (sk) 2009-03-05
NO20030127D0 (no) 2003-01-10
EP1305307A1 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
BRPI0410711A (pt) novos compostos
SE0303180D0 (sv) Novel compounds
BR0214024A (pt) Derivados de 1,2,4-tiadiazol como moduladores de receptor de melanocortina
SE0302232D0 (sv) Novel Compounds
BR0114552A (pt) N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia
EA199700156A1 (ru) Производные индола как антагонисты рецептора 5-нт
SE0201635D0 (sv) Novel compounds
MA27926A1 (fr) Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
BRPI0517955A (pt) indolizinas substituìdas e derivados como agentes de snc
ATE449082T1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
NO970164L (no) Anvendelse av tiazol- og tiadiazolforbindelser som D3 - dopaminreseptorligander
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
DE60322186D1 (de) 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem
MX9605218A (es) Amidas aciclicas y ciclicas novedosas como mejoradores de liberacion de neurotransmisores.
BR0112998A (pt) Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; sua utilização; composição farmacêutica e método de tratamento
AU4038000A (en) 4-substituted quinoline derivatives as gaba receptor ligands
DE60209362D1 (de) 3-substituierte chinolin-4-carbonsäureamidderivate als nk-3- und nk-2-rezeptorantagonisten
ATE247645T1 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
BR0211140A (pt) Compostos e composições de indóis de hexaidroazepina (4, 5-g) e indolinas como ligantes de receptores 5-ht
BR0112286A (pt) Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (cns); composto; sua composição farmacêutica; uso e método para tratamento
NO176097C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte cykloheksener
ATE256678T1 (de) 4-(2-pyridyl)piperazine als agonisten des 5ht7 rezeptors
BR0111764A (pt) Derivados de indol úteis para o tratamento de distúrbios do sistema nervoso central (snc); composto; composição farmacêutica; utilização de composto e método de tratamento

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.